


H-Gly-Pro-Gly-NH₂

Cat. No.:	HY-P4292
CAS No.:	141497-12-3
Molecular Formula:	C ₉ H ₁₆ N ₄ O ₃
Molecular Weight:	228.25
Sequence:	H-Gly-Pro-Gly-NH ₂
Sequence Shortening:	GPG-NH ₂
Target:	HIV; Amino Acid Derivatives
Pathway:	Anti-infection; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	H-Gly-Pro-Gly-NH ₂ is a tripeptide that inhibits HIV-1 replication. H-Gly-Pro-Gly-NH ₂ inhibits the activity of HIV-1 III _B and HIV-2 ROD with EC ₅₀ values of 35 μM and 30 μM, respectively. H-Gly Pro Gly NH ₂ inhibits HIV-1 replication in vitro by interfering with capsid formation. H-Gly Pro Gly NH ₂ has antiviral activity and can be used for virus research ^{[1][2][3]} .																														
IC₅₀ & Target	HIV (IIIB) 35 μM (EC50)	HIV-2 (ROD) 30 μM (EC50)																													
In Vitro	<p>H-Gly-Pro-Gly-NH₂ (5, 20 and 100 μM) shows antiviral activities in HUT78 cells infected with HIV-1 SF-2^[1].</p> <p>H-Gly-Pro-Gly-NH₂ (100 μM) destroys the capsid of HIV-1 virus particles in ACH-2 cells^[1].</p> <p>Antiviral activity of H-Gly-Pro-Gly-NH₂ against clinical HIV-1^[2]</p> <table border="1"> <thead> <tr> <th></th> <th>T215Y/F</th> <th>K70R</th> <th>M184V</th> <th>L74V</th> <th>T69D</th> </tr> </thead> <tbody> <tr> <td>Mean IC₅₀ (μM)</td> <td>16</td> <td>17</td> <td>20</td> <td>12</td> <td>17</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th></th> <th>K103N</th> <th>Y181C</th> <th>G48V</th> <th>L90M</th> <th>V82A/T</th> <th>M46I/L</th> </tr> </thead> <tbody> <tr> <td>Mean IC₅₀ (μM)</td> <td>13</td> <td>21</td> <td>16</td> <td>18</td> <td>16</td> <td>17</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>						T215Y/F	K70R	M184V	L74V	T69D	Mean IC ₅₀ (μM)	16	17	20	12	17		K103N	Y181C	G48V	L90M	V82A/T	M46I/L	Mean IC ₅₀ (μM)	13	21	16	18	16	17
	T215Y/F	K70R	M184V	L74V	T69D																										
Mean IC ₅₀ (μM)	16	17	20	12	17																										
	K103N	Y181C	G48V	L90M	V82A/T	M46I/L																									
Mean IC ₅₀ (μM)	13	21	16	18	16	17																									

REFERENCES

[1]. Höglund S, et al. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. *Antimicrob Agents Chemother.* 2002 Nov;46(11):3597-605.

[2]. Andersson E, et al. No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide[J]. *Antiviral research,* 2004, 61(2): 119-124.

[3]. Balzarini J, et al. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycyprolyglycinamide (GPG-NH(2)). Int J Biochem Cell Biol. 2004 Sep;36(9):1848-59.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA